Trexquant Investment LP acquired a new stake in shares of Alkermes PLC (NASDAQ:ALKS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 4,291 shares of the company’s stock, valued at approximately $218,000.

Several other institutional investors have also added to or reduced their stakes in ALKS. Janus Henderson Group PLC boosted its position in Alkermes by 13,784.0% in the second quarter. Janus Henderson Group PLC now owns 2,330,992 shares of the company’s stock worth $135,128,000 after purchasing an additional 2,314,203 shares during the last quarter. Fiera Capital Corp purchased a new position in Alkermes in the second quarter worth about $37,717,000. Vanguard Group Inc. boosted its position in Alkermes by 3.7% in the second quarter. Vanguard Group Inc. now owns 12,546,198 shares of the company’s stock worth $727,303,000 after purchasing an additional 449,563 shares during the last quarter. First Trust Advisors LP boosted its position in Alkermes by 37.6% in the second quarter. First Trust Advisors LP now owns 979,813 shares of the company’s stock worth $56,800,000 after purchasing an additional 267,742 shares during the last quarter. Finally, Woodford Investment Management Ltd boosted its position in Alkermes by 2.4% in the second quarter. Woodford Investment Management Ltd now owns 7,647,977 shares of the company’s stock worth $443,353,000 after purchasing an additional 177,449 shares during the last quarter. 99.69% of the stock is currently owned by institutional investors.

Several research analysts have issued reports on ALKS shares. Mizuho set a $81.00 target price on Alkermes and gave the stock a “buy” rating in a research report on Saturday, October 21st. ValuEngine cut Alkermes from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. UBS set a $54.00 target price on Alkermes and gave the stock a “hold” rating in a research report on Friday, October 27th. Credit Suisse Group decreased their price objective on Alkermes from $70.00 to $66.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. Finally, Barclays set a $50.00 price objective on Alkermes and gave the stock a “hold” rating in a research note on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. Alkermes has a consensus rating of “Hold” and a consensus price target of $63.55.

In related news, Director Paul J. Mitchell sold 1,500 shares of Alkermes stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $50.64, for a total transaction of $75,960.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Kathryn L. Biberstein sold 13,566 shares of Alkermes stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $51.29, for a total value of $695,800.14. Following the sale, the chief accounting officer now directly owns 70,455 shares in the company, valued at approximately $3,613,636.95. The disclosure for this sale can be found here. Insiders have sold a total of 122,930 shares of company stock worth $6,051,110 in the last three months. 5.34% of the stock is owned by corporate insiders.

Alkermes PLC (NASDAQ ALKS) opened at $52.88 on Friday. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23. Alkermes PLC has a 12 month low of $46.42 and a 12 month high of $63.40.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.04. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The firm had revenue of $217.40 million for the quarter, compared to the consensus estimate of $231.29 million. During the same quarter last year, the company earned ($0.09) earnings per share. The business’s revenue for the quarter was up 20.6% compared to the same quarter last year. analysts predict that Alkermes PLC will post -0.59 EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.dailypolitical.com/2017/12/09/trexquant-investment-lp-acquires-new-stake-in-alkermes-plc-alks.html.

Alkermes Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.